All companies
Visit website
GEROSTATE ALPHA (YC S18)
OperatingGerostate Alpha Inc.
Founded 2018
A pharmaceutical company dedicated to treating aging and age-related disease
Valuation cap ⓘ
$20.0M
As of Nov 2021 · from Gerostate Alpha (YC S18) Future Equity SAFE 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$523,545
Across 3 rounds since 2021
Financials
FY2019–FY2021 · from SEC filings · hover any figure for its source$0
−$922K
2019
$0
−$641K
2020
$0
−$332K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
$0
Net income
-$922,032
-$640,862
-$332,457
Taxes paid
$872
$872
$800
Balance sheet
Cash
$627,109
$302,791
$712,508
Accounts receivable
$0
$0
$0
Total assets
$752,475
$414,210
$767,986
Short-term debt
$51,048
$48,845
$45,353
Long-term debt
$0
$54,800
$0
Total liabilities
$51,048
$103,645
$45,353
Other
Headcount
—
1
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$15.0M
Valuation cap
$20.0M
Valuation cap
Gerostate Alpha (YC S18) Future Equity SAFE 1
Gerostate Alpha (YC S18) Future Equity SAFE 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $252.7K / $4.5MValuation cap $20M
Raised $270.9K / $1.1MInvestors 346Valuation cap $15M
Reg CF annual-report compliance
Delinquent
Filed 1 of 5 annual reports (FY2021–FY2025)
Missing: 2022, 2023, 2024, 2025
346 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001858392
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.